Drug-eluting beads (DEBs) may become a standard of care in the treatment of unresectable liver cancers. DEBs have a significant advantage by offering simultaneous embolisation, and sustained release of antineoplastic agents in a controlled manner, resulting in a localisation of the drug in the targeted tumour, while minimising its systemic exposure. This article reviews current treatment options for liver cancer and concentrates on the benefits of DEBs for patients with unresectable liver cancer. Preclinical and clinical studies suggest smaller microspheres and extended release characteristics as key properties that will enable DEB device technologies to become a standard of care for unresectable liver cancer. A new, tightly size-calibrated DEB ≤100 μm, Embozene TANDEM™, was designed to meet these requirements.
with an associated mortality of >600,000 per year. 2, 3 Underlying cirrhosis is the major risk factor, 2 with an estimated annual risk of developing HCC of 4-8 %. 2, 4 Hepatitis B is responsible for 53-80 % of all cases. 2 Hepatitis C is the major cause of HCC in Japan, the US, Latin America and Europe. 3 Untreated HCC patients have a median survival of 3-8 months. 5 Nearly one million patients are diagnosed with colorectal cancer (CRC)
worldwide every year. 6 Thirty to fifty percent of them develop hepatic metastases (hmCRC); [6] [7] [8] hmCRC is responsible for two-thirds of CRC deaths. 8 One-and five-year survival rates for untreated hmCRC patients are <30 % and <5 %, respectively. 2 Untreated hmCRC has a median survival of 5-10 months.
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Treatment Options
The Barcelona Clinic Liver Cancer (BCLC) staging system is commonly used for HCC. 9 It takes into account underlying liver disease, tumour characteristics and general performance status. 
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LT provides excellent outcomes applying the Milan criteria, with five-year survival rate of 70 % and recurrence rates below 15 %. 12 LT is the only curative option for the underlying cirrhosis. 13, 14 However, because of the shortage of potential liver donors and progression of the HCC, the risk of dropout from liver transplantation waiting lists is up to 4 % per month.
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LR is the treatment of choice for HCC in non-cirrhotic patients (~5 % of cases in Western countries, ~40 % in Asia). 15 In the case of underlying cirrhosis, candidates need to be carefully selected to diminish the risk of post-operative liver failure with increased risk of death. 15, 16 In HCC patients after LR, the risk of tumour recurrence exceeds 70 % at five years. DEBDOX™ (DC Bead loaded with up to 37.5 mg doxorubicin per ml microspheres) was shown in vivo to reduce systemic doxorubicin exposure compared with TACE. [33] [34] [35] In vitro drug-elution showed a low total release (up to 27 %). [36] [37] [38] However, in vivo, 89 % of the initially loaded drug was released within 90 days in a pig model. 39 Histological examination showed a higher degree of necrosis for DEBs (loaded with either doxorubicin or epirubicin) compared with TAE. 40, 41 A randomised trial comparing DEBDOX with TAE showed a statistically significant longer time to progression with DEBDOX. 42 However, there was no difference in survival rates within 12 months between both groups. 42 Although a survival benefit for DEBDOX over TACE was shown in a small retrospective case-controlled study, 43 a large multicentre study showed no significant difference in overall response between DEBDOX and TACE (51.6 % versus 43.5 %, respectively). 44 For patients with more advanced disease (Child-Pugh Drug-eluting Beads in the Treatment of Hepatocellular Carcinoma and Hepatic Metastases HepaSphere is available as a dry formulation and can load similar amounts of doxorubicin to DC Bead. 45, 46 Drug-loading efficiencies of 82-100 % have been reported. 36, 45, 46 In vivo preclinical trials showed sustained drug delivery over a couple of days 46, 47 and reduced peak plasma concentrations for doxorubicin versus TACE. 47 A randomised
Phase II trial comparing doxorubicin-loaded HepaSphere with TACE showed a lower peak plasma concentration and smaller area under the curve for the former. 48 A multicentre trial resulted in high objective response rates with doxorubicin-loaded HepaSphere at one-month and six-month follow-up. 49 Since LR is the only potential curative treatment allowing long-term survival in hmCRC patients, many strategies have been developed to achieve downstaging of initially unresectable tumours.
50
Irinotecan-loaded DEB is quite a novel treatment approach when LR is not feasible and chemotherapy has failed or is ineffective. T/C 54-62 %). 53 Furthermore, in a rabbit VX2 liver tumour model, DEBIRI resulted in lower early serum levels of irinotecan, high and prolonged intratumoural irinotecan level and a higher rate of tumour necrosis at 24 h compared with intra-arterial and intravenous injection. 54 The clinical performance of DEBIRI has been reported in several studies. [55] [56] [57] [58] [59] The median survival has been shown to be 23-25 months, a statistically significant improvement compared with FOLFIRI (folinic acid plus fluorouracil plus irinotecan).
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Embozene TANDEM™ -The Next Step in Drug-eluting Beads Technology
Better tumour penetration of small (100-300 μm) versus larger (300-500 μm) microspheres has been demonstrated in VX2 liver tumour. 62 Potential benefits of small microspheres have been reported in a prospective multi-institutional non-randomised registry for HCC patients 63 and are also suggested for hmCRC patients. [64] [65] [66] [67] In a recent study, increased benefit with decreased size has been shown, with an approximately twofold improved drug coverage in swine kidney (70-150 μm versus 100-300 μm). 68 Thus, microparticles should be small 69 (approximately 50 μm) 2 and tightly size-calibrated with a narrow size distribution. 69 Embozene TANDEM is designed to fulfill the need for:
• size consistency;
• high drug-loading capacity;
• deeper penetration into peripheral tumour vessels; and
• controlled drug release.
Embozene TANDEM is tightly calibrated (40 ± 10 μm, 75 ± 15 μm and 100 ± 25 μm) (see Figure 1 ) and can load 50 mg irinotecan or doxorubicin per ml microspheres with high loading efficiency (98 ± 2%) in short periods of time (30 and 60 minutes for the two drugs, respectively). Different from other DEBs, Embozene TANDEM typically maintains its size after drug loading to allow consistent performance (see Figure 1 ). Size decrease of up to 30 % upon drug loading has been reported for other DEBs depending on the size of microspheres and amount of loaded drug. 38, 51, 70, 71 The high loading capacity of Embozene TANDEM allows to deliver the desired dose and to reach the stasis endpoint by design. The risk of reduced dosage due to premature stasis during intervention is lowered. Embozene TANDEM is available in pre-filled syringes with 2 and 3 ml microspheres. Embozene TANDEM is specifically designed to penetrate into medium/large (35-80 μm) arterioles before blocking blood flow and releasing drug at controlled rates. It offers the smallest microspheres and the tightest calibration on the market.
Release results depend on test set-up and parameters. 36, 38 It has been reported that, under the same conditions, the use of 100-300 μm DEBs resulted in 15-times higher maximum plasma concentrations and in statistically significant lower mean tissue concentrations of doxorubicin compared to 700-900 μm DEBs in a porcine liver model. 39, 40 The expected clinical benefits of controlled drug release are to reduce systemic exposure (improved safety) and increase tumour concentration of doxorubicin (enhanced efficacy). By adapting the structural and chemical compositions of Embozene TANDEM, the desired release rates can be achieved (see Table 1 ).
For irinotecan-loaded DEB, one additional challenge is to reduce drug side effects. 58, 72 Some of the adverse events are related to the initial, fast, and premature release of 5-10 % of the loaded irinotecan for DEBIRI. 58, 73 The release rate of irinotecan is faster than that of doxorubicin. 37, 39, 74 Furthermore, the published in vitro release data demonstrate that the release rate of DEBIRI is size-dependent (see Table 2 ). 51, 52 Consistent with the reported data, 75 investigations in our
Gastrointestinal Cancer (see Table 2 and Figure 2 ). It is important to point out that the release rate of Embozene TANDEM is expected to be even lower in vivo, due to its deep penetration into peripheral tumour vessels with a smaller flow rate. Embozene TANDEM is therefore expected to reduce irinotecan-related side effects.
Conclusion
DEBs are a well established palliative therapy for the treatment of HCC. In the treatment of hmCRC, the role of DEBs is increasing, either as palliative treatment or as downstaging therapy. The trend has been towards smaller microsphere sizes and the need for DEBs ≤100 μm featuring size consistency, high drug-loading capacity, deeper penetration into peripheral tumour vessels and controlled drug-release has emerged. Embozene TANDEM, a new embolic microsphere, is designed to respond to this need. n 
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